The role of sulphonylureas in the management of type 2 diabetes mellitus

Drugs

Volumn 64, Issue 12, 2004, Pages 1339-1358

  Rendell, Marc ^a,b  

^a Creighton Diabetes Center   (United States)

^b Rose Salter Medical Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; ADRENERGIC RECEPTOR STIMULATING AGENT; ALCOHOL; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; BARBITURIC ACID DERIVATIVE; CALCIUM CHANNEL; CLOFIBRATE; DIAZOXIDE; DIURETIC AGENT; ESTROGEN DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOCORTICOID; INSULIN DERIVATIVE; MEGLITINIDE; METFORMIN; MONOAMINE OXIDASE INHIBITOR; NATEGLINIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; POTASSIUM CHANNEL; REPAGLINIDE; RIFAMPICIN; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG;

BLOOD DYSCRASIA; CARBOHYDRATE ABSORPTION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; EXOCYTOSIS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCOGEN SYNTHESIS; HEART LEFT VENTRICLE FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; INSULIN INFUSION; INSULIN RELEASE; ISCHEMIA; LEUKOPENIA; LIPOGENESIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSTRUCTIVE JAUNDICE; PANCREAS ISLET BETA CELL; PHOTOSENSITIVITY; PROTEIN BINDING; PRURITUS; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIC PURPURA; TRANSLUMINAL CORONARY ANGIOPLASTY; VOMITING;

BENZAMIDES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; SULFONYLUREA COMPOUNDS; TREATMENT FAILURE;

PURPURA;

EID: 3142728651     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464120-00006     Document Type: Review

References (303)

1. Loubatieres A. The hypoglycemic sulfonamides: history and development of the problem from 1942 to 1955, Ann N Y Acad Sci 1957; 71: 4-11
2. Gotfredsen CF, Dynamics of sulfonylurea-induced insulin release from the isolated perfused rat pancreas. Diabetologia 1976; 12: 339-42
3. Kolterman OG, Olefsky JM. The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes. Diabetes Care 1984; 7 Suppl. 1: 81-8
4. Schwanstecher M, Sieverding C, Dorschner H, et al. Potassium channel openers require ATP to bind to and act through sulfonylurea receptors. EMBO J 1998; 17: 5529-35
5. Dorschner H, Brekardin E, Uhde I, et al. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure. Mol Pharmacol 1999; 55: 1060-6
6. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 1999; 20: 101-35
7. John SA, Weiss JN, Ribalet B. Regulation of cloned ATP-sensitive K channels by adenine nucleotides and sulfonylureas: interactions between SUR1 and positively charged domains on Kir6.2. J Gen Physiol 2001; 118: 391-405
8. + channels. Biochim Biophys Acta 1999; 1461: 285-303
9. Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol 2001; 431: 119-25
10. Loffler-Walz C, Hambrock A, Quast U. Interaction of K(ATP) channel modulators with sulfonylurea receptor SUR2B: implication for tetramer formation and allosteric coupling of subunits. Mol Pharmacol 2002; 61: 407-14
11. Sim JH, Yang DK, Kim YC, et al. ATP-sensitive K(+) channels composed of Kir6.1 and SUR2B subunits in guinea pig gastric myocytes. Am J Physiol Gastrointest Liver Physiol 2002; 282: G137-44
12. Taguchi T, Suita S, Ohkubo K, et al. Mutations in the sulfonylurea receptor gene in relation to the long-term outcome of persistent hyperinsulinemic hypoglycemia of infancy. J Pediatr Surg 2002; 37: 593-8
13. Grimberg A, Ferry Jr RJ, Kelly A, et al. Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes 2001; 50: 322-8
14. Huopio H, Vauhkonen I, Komulainen J, et al. Carriers of an inactivating beta-cell ATP-sensitive K(+) channel mutation have normal glucose tolerance and insulin sensitivity and appropriate insulin secretion. Diabetes Care 2002; 25: 101-6
15. McCaleb ML, Maloff BL, Nowak SM, et al. Sulfonylurea effects on target tissues for insulin. Diabetes Care 1984; 7 Suppl. 1: 42-6
16. Keller U, Muller R, Berger W. Sulfonylurea therapy fails to diminish insulin resistance in type I-diabetic subjects. Horm Metab Res 1986; 18: 599-603
17. da Tos V, Maran A, Vigili de Kreutzenberg S, et al. Mechanisms of acute and chronic hypoglycemic action of gliclazide. Acta Diabetol 2000; 37: 201-6
18. Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas: a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995; 28 Suppl. 1: S115-37
19. Muller G, Wied S. The Sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 1993; 42: 1852-67
20. Bahr M, von Holtey M, Muller G, et al. Direct stimulation of myocardial glucose transport and glucose transporter-1 (GLUT1) and GLUT4 protein expression by the sulfonylurea glimepiride. Endocrinology 1995; 136: 2547-53
21. Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 3140-5
22. Cejvan K, Coy DH, Holst JJ, et al. Gliclazide directly inhibits arginine-induced glucagon release. Diabetes 2002; 51 Suppl. 3: S381-4
23. ter Braak EW, Appelman AM, van der Tweel I, et al. The sulfonylurea glibenclamide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia. Diabetes Care 2002; 25: 107-12
24. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-54
25. Melander A, Bitzen PO, Faber O, et al. Sulphonylurea antidiabetic drugs, an update of their clinical pharmacology and rational therapeutic use. Drugs 1989; 37; 58-72
26. Prendergast BD. Glibenclamide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. Clin Pharm 1984; 3: 473-85
27. Kennedy DL, Piper JM, Baum C. Trends in the use of oral hypoglycemic agents, 1964-1986. Diabetes Care 1988; 11: 558-62
28. Langtry HD, Balfour JA. Glimepiride: a review of its use in the management of type 2 diabetes mellitus. Drugs 1998; 55: 563-84
29. Rosenstock J, Samols E, Muchmore DB, et al. Glimepiride, a new once daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care 1996; 19: 1194-9
30. Ylitalo P, Oksala H, Pitkajarvi T. Comparison of acute and prolonged effects of glibenclamide and chlorpropamide in patients with non-insulin-dependent diabetes. Arzneimittelforschung 1985; 35: 1596-9
31. Matz R. Hyponatremia and sulfonylureas. Diabetes Care 1984; 7: 201-2
32. Skillman TG, Feldman JM. The pharmacology of sulfonylureas. Am J Med 1981; 70: 361-72
33. Berger W. Incidence of severe side effects during therapy with sulfonylureas and biguanides. Horm Metab Res Suppl 1985; 15: 111-5
34. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223-41
35. Burge MR, Zeise TM, Sobhy TA, et al. Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. Diabetes Care 1999; 22: 2037-43
36. Lao B, Czyzyk A, Szutowski M, et al. Alcohol tolerance in patients with non-insulin-dependent (type 2) diabetes treated with honylurea derivatives. Arzneimittelforschung 1994; 44: 727-34
37. Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf 2000; 22: 313-20
38. Feldman JM. Glibenclamide: a second-generation sulfonylurea hypoglycemic agent. Pharmacotherapy 1985; 5: 43-62
39. Pearson JG. Pharmacokinetics of glibenclamide. Am J Med 1985; 79 Suppl. 3B: 67-71
40. Coppack SW, Lant AF, McIntosh CS, et al. Pharmacokinetics and pharmacodynamics studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Clin Pharmacol 1990; 29: 673-84
41. El-Sayed YM, Suleiman MS, Hasan MM, et al. Comparison of the pharmacokinetics and pharmacodynamics of two commercial products containing glibenclamide. Int J Clin Pharmacol Ther Toxicol 1989; 27: 551-7
42. Neuvonen PJ, Kivisto KT. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations. Br J Clin Pharmacol 1991; 32: 215-20
43. Ings RMJ, Lawerence JR, McDonald A, et al. Glibenclamide pharmacokinetics in healthy volunteers: evidence for zero-order drug absorption. Br J Clin Pharmacol 1981; 13: 264P-5P
44. Jonsson A, Rydberg T, Ekberg G, et al. Slow elimination of glibenclamide in NIDDM subjects. Diabetes Care 1994; 17: 142-5
45. Rydberg T, Jonsson A, Karlsson MO, et al. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1997; 43: 373-81
46. Jonsson A, Hallengren B, Rydberg T, et al. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab 2001; 3: 403-9
47. Pearson JG, Antal EJ, Raehl CL, et al. Pharmacokinetic disposition of C14-glibenclamide in patients with varying renal function. Clin Pharmacol Ther 1986; 39: 318-24
48. Wan Mohamad WB, Tun Fizi A, Ismail RB, et al. Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus. Diabetes Res Clin Pract 2000; 49: 93-9
49. Jonsson A, Chan JC, Rydberg T, et al. Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes. Eur J Clin Pharmacol 2000; 55: 721-7
50. Kobayashi K, Kimura M, Sakoguchi T, et al. Influence of blood proteins on biomedical analysis: III. pharmacokinetics and protein binding of gliclazide. J Pharmacobiodyn 1981; 4: 436-42
51. Davis TME, Daly F, Walsh JP, et al. Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. Br J Clin Pharmacol 2000; 49: 223-30
52. Fujii T, Nakamura K, Furukawa H, et al. Drug interactions of gliclazide and other sulfonylureas in protein binding in vitro and in hypoglycemic effect in rats. Arzneimittelforschung 1983; 33: 1535-7
53. Abad S, Moachon L, Blanche P, et al. Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia. Br J Clin Pharmacol 2001; 52: 456-7
54. Park JY, Kim KA, Park PW, et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin Pharmacol Ther 2003; 74: 334-40
55. Diamicron prescribing information. Slough: Servier Laboratories, 1997
56. Pentikainen PJ, Neuvonen PJ, Penttila A, Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1983; 21: 98-107
57. Kradjan WA, Takeuchi KY, Opheim KE, et al. Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. Pharmacotherapy 1995; 15: 465-71
58. Lebovitz HE. Glipizide: a second-generation sulfonylurea hypoglycemic agent: pharmacology, pharmacokinetics and clinical use. Pharmacotherapy 1985; 5: 63-77
59. Melander A, Wahlin-Boll E. Clinical pharmacology of glipizide. Am J Med 1983; 75: 41-5
60. Kradjan WA, Kobayashi KA, Bauer LA, et al. Glipizide pharmacokinetics: effects of age, diabetes, and multiple dosing. J Clin Pharmacol 1989; 29: 1121-7
61. Kobayashi KA, Bauer LA, Horn JR, et al. Glipizide pharmacokinetics in young and elderly volunteers. Clin Pharm 1988; 7: 224-8
62. Niemi M, Cascorbi I, Timm R, et al. Glibenclamide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72: 326-32
63. Ahren B, Lundquist I, Schersten B. Effects of glipizide on various consecutive insulin secretory stimulations in patients with type 2 diabetes. Diabetes Res 1986; 3: 293-300
64. Bitzen PO, Melander A, Schersten B, et al. Long-term effects of glipizide on insulin secretion and blood glucose control in patients with non-insulin-dependent diabetes mellitus. Eur J Clin Pharmacol 1992; 42: 77-83
65. Jaber LA, Ducharme MP, Edwards DJ, et al. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. Pharmacotherapy 1996; 16: 760-8
66. Hartling SG, Faber OK, Wegmann ML, et al. Interaction of ethanol and glipizide in humans. Diabetes Care 1987; 10: 683-6
67. Johnson JF, Dobmeier ME. Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. DICP 1990; 24: 250-1
68. Kivisto KT, Neuvonen PJ. Enhancement of absorption and effect of glipizide by magnesium hydroxide. Clin Pharmacol Ther 1991; 49: 39-43
69. Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol 1993; 35: 321-3
70. Glucotrol prescribing information. New York: Pfizer, 2000
71. Kramer W, Muller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res 1996; 28: 464-8
72. Ratheiser K, Korn A, Waldhausl W, et al. Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man. Arzneimittelforschung 1993; 43: 856-8
73. Singh J, Unnikrishnan AG, Agrawal NK, et al. Immunoreactive insulin response to a single dose of glimepiride in lean type 2 diabetic subjects. J Assoc Physicians India 2002; 50: 1232-5
74. van der Wal PS, Draeger KE, van Iperen AM, et al. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients. Diabet Med 1997; 14: 556-63
75. Gregorio F, Ambrosi F, Cristallini S, et al. Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations. Acta Diabetol 1996; 33: 25-9
76. Korytkowski M, Thomas A, Reid L, et al. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 1607-11
77. Sato I, Ohsawa I, Oshida Y, et al. Comparison of the effects of three sulfonylureas on in vivo insulin action. Arzneimittelforschung 2001; 51: 459-64
78. Muller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Mol Med 2000; 6: 907-33
79. Badian M, Korn A, Lehr KH, et al. Absolute bioavailability of glimepiride (Amaryl) after oral administration. Drug Metabol Drug Interact 1994; 11: 331-9
80. Badian M, Korn A, Lehr KH, et al. Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. Drug Metabol Drug Interact 1996; 13: 69-85
81. Niemi M, Neuvonen PJ, Kivisto KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001; 70: 439-45
82. Niemi M, Backman JT, Neuvonen M, et al. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001; 69: 194-200
83. Niemi M, Kivisto KT, Backman JT, et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. Br J Clin Pharmacol 2000; 50: 591-5
84. Malerczyk V, Badian M, Korn A, et al. Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers. Drug Metabol Drug Interact 1994; 11: 341-57
85. Rosenkranz B, Profozic V, Metelko Z, et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996; 39: 1617-24
86. Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res 1996; 28: 434-9
87. Carlson RF, Isley WL, Ogrinc FG, et al. Efficacy and safety of reformulated, micronized glibenclamide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial. Clin Ther 1993; 15: 788-96
88. Chung M, Kourides I, Canovatchel W, et al. Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. J Clin Pharmacol 2002; 42: 651-7
89. Simonson DC, Kourides IA, Feinglos M, et al. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 1997; 20: 597-606
90. Berelowitz M, Fischette C, Cefalu W, et al. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 1994; 17: 1460-4
91. McGavin JK, Perry CM, Goa KL. Gliclazide modified release. Drugs 2002; 62: 1357-64
92. Frey N, Laveille C, Paraire M, et al. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol 2003; 55: 147-57
93. Kilo C, Meenan A, Bloomgarden Z. Glibenclamide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus. Clin Ther 1992; 14: 801-12
94. Groop L, Groop P-H, Stenman S, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glibenclamide and glipizide during long-term treatment. Diabetes Care 1987; 10: 671-7
95. Cozma LS, Luzio SD, Dunseath GJ, et al. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. J Clin Pharmacol 2002; 42: 651-7
96. Groop L, Luzi L, Melander A, et al. Different effects of glibenclamide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987; 36: 1320-8
97. Groop L, Wahlin-Boll E, Groop PH, et al. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics. Eur J Clin Pharmacol 1985; 28; 697-704
98. van Staa T, Abenhaim L, Monette J. Rates of hypoglycaemia in users of sulfonylureas. J Clin Epidemiol 1997; 50: 735-41
99. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycaemia in NDDM patients treated with oral hypoglycaemic agents. Diabetes Care 1989; 12: 203-31
100. Berger W, Caduff F, Pasquel M, et al. The relatively frequent incidence of severe sulfonylurea-induced hypoglycaemia in the last 25 years in Switzerland: results of 2 surveys in Switzerland in 1969 and 1984. Schweiz Med Wochenschr 1986; 116: 145-51
101. Stenman S, Melander A, Groop PH, et al. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993; 118: 169-72
102. Birkeland KI, Furuseth K, Melander A, et al. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glibenclamide: glycemic control and insulin secretion during 15 months. Diabetes Care 1994; 17: 45-9
103. Simcic KJ, McDermott MT, White JC, et al. Crossover comparison of maximum dose glibenclamide and glipizide. South Med J 1991; 84: 743-6
104. Raptis SA, Hatziagelaki E, Dimitriadis G, et al. Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man. Exp Clin Endocrinol Diabetes 1999; 107: 350-5
105. Clark HE, Matthews DR. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperin-sulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm Metab Res 1996; 28: 445-50
106. Sato J, Ohsawa I, Oshida Y, et al. Comparison of effects of three sulfonylureas on in vivo insulin action. Arzneimittelforschung 2001; 51: 459-64
107. Lindblad U, Melander A. Sulphonylurea dose-response relationships: relation to clinical practice. Diabetes Obes Metab 2000; 2: 25-31
108. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents: the Glimepiride Protocol #201 Study Group. Diabetes Care 1996; 19: 849-56
109. Rosenstock J, Samols E, Muchmore DB, et al. Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 1996; 19: 1194-9
110. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998; 32: 1044-52
111. Groop L, Schalin C, Franssila-Kallunki A, et al. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med 1989; 87: 183-90
112. Groop LC, Pelkonen R, Koskimies S, et al. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 1986; 9: 129-33
113. Chow CC, Tsang LW, Sorensen JP, et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995; 18: 307-14
114. Fanghanel G, Sanchez-Reyes L, Trujillo C, et al. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care 1996; 19: 1185-9
115. Pontiroli AE, Calderara A, Pozza G. Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab Rev 1994; 10: 31-43
116. Yildiz BO, Gurlek A. Failure of sulfonylureas in type 2 diabetes. Horm Metab Res 1999; 31: 293-4
117. Taverna MJ, Pacher N, Bruzzo F, et al. Beta-cell function evaluated by HOMA as a predictor of secondary sulphonylurea failure in type 2 diabetes. Diabet Med 2001; 18: 584-8
118. Sami T, Kabadi UM, Moshiri S. The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents. J Fam Pract 1996; 43: 370-4
119. Ling Z, Kiekens R, Mahler T, et al. Effects of chronically elevated glucose levels on the functional properties of rat pancreatic beta-cells. Diabetes 1996; 45: 1774-82
120. Sivitz WI. Lipotoxicity and glucotoxicity in type 2 diabetes: effects on development and progression. Postgrad Med 2001; 109: 55-9, 63-4
121. Poitout V, Robertson RP. Minireview: secondary beta-cell failure in type 2 diabetes: a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-42
122. Kaiser N, Leibowitz G, Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2003; 16: 5-22
123. Malaisse WJ, Marynissen G, Sener A. Possible role of glycogen accumulation in B-cell glucotoxicity. Metabolism 1992; 41: 814-9
124. Liu YQ, Tornheim K, Leahy JL. Shared biochemical properties of glucotoxicity and lipotoxicity in islets decrease citrate synthase activity and increase phosphofructokinase activity. Diabetes 1998; 47: 1889-93
125. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-60
126. Karam JH. Reversible insulin resistance in non-insulin-dependent diabetes mellitus. Horm Metab Res 1996; 28: 440-4
127. Buren J, Lindmark S, Renstrom F, et al. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo? Metabolism 2003; 52: 239-45
128. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-6
129. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-12
130. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998; 15: 297-303
131. Landstedt-Hallin L, Arner P, Lins PE, et al. The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal: Scandinavian Insulin-Sulphonylurea Study Group Research Team. Diabet Med 1999; 16: 827-34
132. Kobayashi T, Nakanishi K, Murase T, et al. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45: 622-6
133. Fukui M, Nakano K, Maruya E, et al. Diagnostic significance of antibodies to glutamic acid decarboxylase in Japanese diabetic patients with secondary oral hypoglycemic agents failure. Clin Immunol Immunopathol 1997; 85: 182-6
134. Rattarasarn C, Aguilar Diosdado M, Soonthornpun S. Glutamic acid decarboxylase antibodies in non-insulin-dependent diabetes patients with secondary sulfonylurea failure in Thailand. Diabetes Res Clin Pract 1997; 37: 193-7
135. Harrower AD. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications 1994; 8: 201-3
136. Bastyr III EJ, Johnson ME, Trautmann ME, et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999; 21: 1703-14
137. Ross SA, Zinman B, Campos RV, et al. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 2001; 24: 292-8
138. Feinglos MN, Thacker CH, English J, et al. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997; 20: 1539-42
139. Riddle MC. Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. Horm Metab Res 1996; 28: 430-3
140. Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995; 44: 165-72
141. Ravnik-Oblak M, Mrevlje F. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure. Diabetes Res Clin Pract 1995; 30: 27-35
142. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156: 259-64
143. Landstedt-Hallin L, Adamson U, Arner P, et al. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995; 18: 1183-6
144. Clauson P, Karlander S, Steen L, et al. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up. Diabet Med 1996; 13: 471-7
145. Olsson PO, Lindstrom T. Combination-therapy with bedtime NPH insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. Diabetes Metab 2002; 28: 272-7
146. Castillo M, Scheen AJ, Paolisso G, et al. The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Acta Endocrinol (Copenh) 1987; 116: 364-72
147. Feinglos MN, Thacker CR, Lobaugh B, et al. Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus. Diabetes Res Clin Pract 1998; 39: 193-9
148. Abraira C, Henderson WG, Colwell JA, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes: VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998; 21: 574-9
149. Binder C, Bendtson I. Endocrine emergencies: hypoglycaemia. Baillieres Clin Endocrinol Metab 1992; 6: 23-39
150. Marks V, Teale JD. Drug-induced hypoglycemia. Endocrinol Metab Clin North Am 1999; 28: 555-77
151. Burge MR, Schmitz-Fiorentino K, Fischette C, et al. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA 1998; 279: 137-43
152. Chan TY. Anti-diabetic drugs as a cause of hypoglycaemia among acute medical admissions in Hong Kong and Singapore: relationship to the prescribing patterns in diabetic patients. Singapore Med J 1998; 39: 186-8
153. Ben-Ami H, Nagachandran P, Mendelson A, et al. Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 1999; 159: 281-4
154. Holstein A, Plaschke A, Hammer C, et al. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 2003; 59; 91-7
155. Salas M, Caro JJ. Are hypoglycaemia and other adverse effects similar among sulphonylureas? Adverse Drug React Toxicol Rev 2002; 21: 205-17
156. Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001; 161: 1653-9
157. Holstein A, Plaschke A, Egberts EH. Clinical characterisation of severe hypoglycaemia: a prospective population-based study. Exp Clin Endocrinol Diabetes 2003; 111: 364-9
158. Marker JC, Cryer PE, Clutter WE. Attenuated glucose recovery from hypoglycemia in the elderly. Diabetes 1992; 41: 671-8
159. Matyka K, Evans M, Lomas J, et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997; 20: 135-41
160. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681-6
161. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000; 35: 500-5
162. Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996; 31: 111-9
163. Graal MB, Wolffenbuttel BH. The use of sulphonylureas in the elderly. Drugs Aging 1999; 15: 471-81
164. Desouza C, Salazar H, Cheong B, et al. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003; 26: 1485-9
165. Thamer M, Ray NF, Taylor T. Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas. Clin Ther 1999; 21: 1387-400
166. Oltmanns KM, Deininger E, Wellhoener P, et al. Influence of captopril on symptomatic and hormonal responses to hypoglycaemia in humans. Br J Clin Pharmacol 2003; 55: 347-53
167. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997; 44: 513-8
168. Spiller HA. Management of antidiabetic medications in overdose. Drug Saf 1998; 19: 411-24
169. McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med 2000; 36: 133-8
170. Harrigan RA, Nathan MS, Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med 2001; 38: 68-78
171. Kaufman DW, Kelly JP, Johannes CB, et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993; 82: 2714-8
172. Scheen AJ, Lefebvre PJ. Pharmacological treatment of the obese diabetic patient. Diabete Metab 1993; 19: 547-59.
173. Merlob P, Levitt O, Stahl B. Oral antihyperglycemic agents during pregnancy and lactation: a review. Paediatr Drugs 2002; 4: 755-60
174. Langer O, Conway DL, Berkus MD, et al. A comparison of glibenclamide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343: 1134-8
175. Goetzl L, Wilkins I. Glibenclamide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis. J Perinatol 2002; 22: 403-6
176. UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53
177. Hiraoka M. Pathophysiological functions of ATP-sensitive K+ channels in myocardial ischemia. Jpn Heart J 1997; 38: 297-315
178. Pomerantz BJ, Robinson TN, Heimbach JK, et al. Selective mitochondrial KATP channel opening controls human myocardial preconditioning: too much of a good thing? Surgery 2000; 128: 368-73
179. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998; 31: 950-6
180. Howes LG, Sundaresan P, Lykos D. Cardiovascular effects of oral hypoglycaemic drugs. Clin Exp Pharmacol Physiol 1996; 23: 201-6
181. Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S, et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002; 51: 808-12
182. Schotborgh CE, Wilde AA. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Cardiovasc Res 1997; 34: 73-80
183. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-24
184. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88: 531-7
185. Ballagi-Pordany G, Koszeghy A, Koltai MZ, et al. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Res Clin Pract 1990; 8: 109-14
186. Geisen K, Vegh A, Krause E, et al. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 1996; 28: 496-507
187. Schaffer SW, Warner BA, Wilson GL. Effects of chronic glipizide treatment on the NIDD heart. Horm Metab Res 1993; 25: 348-52
188. Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complications 2000; 14: 192-6
189. Gribble FM, Ashcroft FM. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 2000; 49 Suppl. 2: 3-6
190. Legtenberg RJ, Houston RJ, Oeseburg B, et al. Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart. Eur J Pharmacol 2001; 419: 85-92
191. Nieszner E, Posa I, Kocsis E, et al. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits. Exp Clin Endocrinol Diabetes 2002; 110: 212-8
192. del Valle HF, Lascano EC, Negroni JA, et al. Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep. Cardiovasc Res 2001; 50: 474-85
193. Lomuscio A, Vergani D, Marano L, et al. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coron Artery Dis 1994; 5: 767-71
194. Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm Metab Res 1995; 27: 263-6
195. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001; 358: 1709-16
196. Grell W, Hurnaus R, Griss G, et al. Repaglinide and related hypoglycemic benzole acid derivatives. J Med Chem 1998; 41: 5219-46
197. Hatorp V, Oliver S, Su CA. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int J Clin Pharmacol Ther 1998; 36: 636-41
198. Hatorp V, Huang WC, Strange P. Repaglinide pharmacokinetics in healthy young adult and elderly subjects. Clin Ther 1999; 21: 702-10
199. Balfour JA, Faulds D. Repaglinide. Drugs Aging 1998; 13: 173-80
200. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Ionophoretic activity of meglitinide analogues. Diabetes Res 1994; 27: 61-71
201. Malaisse WJ. Insulinotropic action of meglitinide analogues: modulation by an activator of ATP-sensitive K+ channels and high extracellular K+ concentrations. Pharmacol Res 1995; 32: 111-4
202. Malaisse WJ. Mechanism of action of a new class of insulin secretagogues. Exp Clin Endocrinol Diabetes 1999; 107 Suppl. 4: S140-3
203. Gromada J, Dissing S, Kofod H, et al. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995; 38: 1025-32
204. Dabrowski M, Wahl P, Holmes WE, et al. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. Diabetologia 2001; 44: 747-56
205. Ladriere L, Malaisse-Lagae F, Fuhlendorff J, et al. Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats. Eur J Pharmacol 1997; 335: 227-34
206. Owens DR. Repaglinide: prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med 1998; 15 Suppl. 4: S28-36
207. Pratley RE, Foley JE, Dunning BE. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des 2001; 7: 1375-97
208. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-51
209. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glibenclamide for the treatment of type 2 diabetes: Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22: 463-7
210. Gomis R. Repaglinide as monotherapy in Type 2 diabetes. Exp Clin Endocrinol Diabetes 1999; 107 Suppl. 4: S133-5
211. Owens DR, Luzio SD, Ismail I, et al. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000; 23: 518-23
212. Strange P, Schwartz SL, Graf RJ, et al. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes. Diabetes Technol Ther 1999; 1: 247-56
213. Schatz H. Preclinical and clinical studies on safety and tolerability of repaglinide. Exp Clin Endocrinol Diabetes 1999; 107 Suppl. 4: S144-8
214. Damsbo P, Clauson P, Marbury TC, et al. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glibenclamide in well-controlled type 2 diabetic patients. Diabetes Care 1999; 22: 789-94
215. Jovanovic L, Dailey III G, Huang WC, et al. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000; 40: 49-57
216. Damsbo P, Marbury TC, Hatorp V, et al. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes. Diabetes Res Clin Pract 1999; 45: 31-9
217. Mafauzy M. Repaglinide versus glibenclamide treatment of type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002; 58: 45-53
218. Wolffenbuttel BH, Nijst L, Sels JP, et al. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulfonylurea-treated patients with NIDDM. Eur J Pharmacol 1993; 45: 113-6
219. Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998; 21: 1897-903
220. Madsbad S, Kilhovd B, Lager I, et al. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabet Med 2001; 18: 395-401
221. CuLy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61: 1625-6
222. Raskin P, Jovanovic L, Berger S, et al. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. Diabetes Care 2000; 23: 979-83
223. Moses R. Repaglinide in combination therapy with metformin in type 2 diabetes. Exp Clin Endocrinol Diabetes 1999; 107 Suppl. 4: S136-9
224. de Luis DA, Aller R, Cuellar L, et al. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 1844-55
225. Furlong NJ, Hulme SA, O'Brien SV, et al. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes Care 2002; 25: 1685-90
226. Marbury TC, Ruckle JL, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000; 67: 7-15
227. Schumacher S, Abbasi I, Weise D, et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001; 57: 147-52
228. Hatorp V, Walther KH, Christensen MS, et al. Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease. J Clin Pharmacol 2000; 40: 142-52
229. Chachin M, Yamada M, Fujita A, et al. Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels. J Pharmacol Exp Ther 2003; 304: 1025-32
230. Hu S, Wang S, Fanelli B, et al. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 2000; 293: 444-52
231. Hansen AM, Christensen IT, Hansen JB, et al. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes 2002; 51: 2789-95
232. Hu S, Boettcher BR, Dunning BE. The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia 2003; 46 Suppl. 1: M37-43
233. Hu S. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action. Eur J Pharmacol 2002; 442: 163-71
234. Kahn SE, Montgomery B, Howell W, et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 5824-9
235. Hu S, Wang S, Dunning BE. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide. Int J Exp Diabetes Res 2001; 2: 63-72
236. Saloranta C, Guitard C, Pecher E, et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care 2002; 25: 2141-6
237. Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: comparison of nateglinide and glibenclamide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001; 24: 983-8
238. Salas M, Ward A, Caro J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clin Ther 2002; 24: 1690-705
239. Marre M, Van Gaal L, Usadel KH, et al. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 2002; 4: 177-86
240. Rosenstock J, Shen SG, Gatlin MR, et al. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002; 25: 1529-33
241. Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl 2000; 113: 3-13
242. Arner P, Pollare T, Lithell H. Different aetiologies of type 2 (noninsulin-dependent) diabetes mellitus in obese and nonobese subjects. Diabetologia 1991; 34: 483-7
243. Gerich J. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998; 19: 491-503
244. Vaag A, Henriksen J, Madsbad S, et al. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest 1995; 95: 690-8
245. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled trial. Am J Med 1997; 103 (6): 491-7
246. UKPDS Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with 1 type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65
247. Radziuk J, Zhang Z, Wiernsperger N, et al. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 1997; 46: 1406-13
248. Minassian C, Tarpin S, Mithieux G. Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin. Biochem Pharmacol 1998; 55: 1213-9
249. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-9
250. Chu CA, Wiernsperger N, Muscato N, et al. The acute effect of metformin on glucose production in the conscious dog is primarily attributable to inhibition of glycogenolysis. Metabolism 2000; 49: 1619-26
251. Song S, Andrikopoulos S, Filippis C, et al. Mechanism of fatinduced hepatic gluconeogenesis: effect of metformin. Am J Physiol Endocrinol Metab 2001; 281: E275-82
252. Gugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44: 107-12
253. Jenkins DJ, Taylor RH, Goff DV, et al. Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 1981; 30: 951-4
254. Gray RS, Olefsky JM. Effect of a glucosidase inhibitor on the metabolic response of diabetic rats to a high carbohydrate diet, consisting of starch and sucrose, or glucose. Metabolism 1982; 31: 88-92
255. Taylor RH, Barker HM, Bowey EA, et al. Regulation of the absorption of dietary carbohydrate in man by two new glycosidase inhibitors. Gut 1986; 27: 1471-8
256. Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000; 59: 521-49
257. Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998; 83: 1515-22
258. Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001; 276: 41245-54
259. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002; 34: 217-24
260. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18 Suppl. 2: S10-5
261. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-74
262. Tordjman J, Chauvet G, Quette J, et al. Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. J Biol Chem 2003; 278: 18785-90
263. Itoh H, Doi K, Tanaka T, et al. Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor γ. Clin Exp Pharmacol Physiol 1999; 26 (7): 558-60
264. Yoshimoto T, Naruse M, Shizume H, et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 1999; 145: 333-40
265. Martens FM, Visseren FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62: 1463-80
266. Benbow A, Stewart M, Yeoman G. Thiazolidinediones for type 2 diabetes: all glitazones may exacerbate heart failure [letter]. BMJ 2001 Jan 27; 322 (7280): 236
267. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002 Jul; 22 (7): 924-9
268. Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 2003 Feb; 46 (2): 288-90
269. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63 (13): 1373-405
270. Hermann LS, Schersten B, Bitzen PO, et al. therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double blind controlled study. Diabetes Care 1994; 17: 1100-9
271. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108 Suppl 6a: 15S-22S
272. Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebo-controlled trial comparing acarbose (BAYg 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-51
273. Segal P, Feig PU, Schernthaner G, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 1997; 20: 687-91
274. Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ, et al. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diabete Metab 1995; 21: 256-60
275. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-9
276. Erle G, Lovise S, Stocchiero C, et al. A comparison of preconstituted, fixed combinations of low-dose glibenclamide plus metformin versus high-dose glibenclamide alone in the treatment of type 2 diabetic patients. Acta Diabetol 1999; 36: 61-5
277. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glibenclamide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002; 4: 201-8
278. Nathan DM. Some answers, more controversy, from UKPDS: United Kingdom Prospective Diabetes Study. Lancet 1998; 352: 832-3
279. Fisman EZ, Tenenbaum A, Benderly M, et al. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 1999; 91: 195-202
280. Yale JF, Valiquett TR, Ghazzi MN, et al. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: a multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 737-45
281. Horton ES, Whitehouse F, Ghazzi MN, et al. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes: the Troglitazone Study Group. Diabetes Care 1998; 21: 1462-9
282. Rosenstock J, Kreider M, Menci L, et al. Efficacy and safety of rosiglitazone combined with glibenclamide is effective and well tolerated in type 2 diabetic patients inadequately controlled on maximum-dose glibenclamide [abstract]. Diabetes Res Clin Pract 2000; 50 Suppl. 1: S61
283. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Am J Med 2001; 111: 10-7
284. Wolffenbuttel BHR, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycemic control in type 2 diabetic patients. Diabet Med 2000; 17: 40-7
285. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-72
286. Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003; 52: 283-90
287. Hallsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002 Dec; 51 (12): 3479-85
288. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695-702
289. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22: 1395-409
290. Rendell M, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabet Complications 2003; 17: 211-7
291. Gavin LA, Earth J, Arnold D, Shaw R. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. Endocr Pract 2000 Jul-Aug; 6 (4): 305-310
292. Bell DS, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract 2002; 8: 271-5
293. Yki-Jarvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2002; 18 Suppl. 3: S77-81
294. HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet Med 2003; 20: 545-51
295. Fritsche A, Schweitzer MA, Haring HU, et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2003; 138: 952-9
296. Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002; 25: 1691-8
297. Wulffele MG, Kooy A, Lehert P, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25: 2133-40
298. Schwartz S, Sievers R, Strange P, et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003; 26: 2238-43
299. Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone: Glimepiride Combination Group. Diabetes Care 1998; 21: 1052-7
300. Riddle MC. New tactics for type II diabetes: regimens based on intermediate-acting insulin taken at bedtime. Lancet 1985; I: 192-251
301. Riddle MC, Hart JS, Bouma DJ, et al. Efficacy of bedtime NPH insulin with daytime sulfonylurea for a subpopulation of Type II diabetes mellitus. Diabetes Care 1989; 12: 623-9
302. Riddle MC. Evening insulin strategy. Diabetes Care 1990; 13: 676-86
303. Groop LC, Widen E, Ekstrand A, et al. Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM. Diabetes Care 1992; 15: 831-4